Model PAD4 -High Anti-CCP (Anti-Cyclic Citrullinated Peptide)
Strong scientific and clinical rationale for PAD4 inhibitors in autoimmune disorders.
Most popular related searches
autoimmune disorder
immune suppressive
COVID 19
disease progression
immune suppressing
immune suppression
lung fibrosis
autoimmune disease
autoimmune
psoriasis
- Differentiated first-in-class mechanism to treat autoimmune diseases
- Broader application in various auto-immune disorders such as lung fibrosis (including Covid-19 ARDS), psoriasis, SLE, DVT
- Potential utility in niche indications such as Bullous Pemphigoid and Behcet’s diseases
- Next generation target in autoimmune/inflammation beyond JAKs and TNFs
- High anti-CCP (anti-cyclic citrullinated peptide) levels are detected in RA patients
- Histone citrullination and associated NET formation linked to pro-inflammation and disease progression in several autoimmune disorders including RA, psoriasis, thrombosis, fibrosis, SLE etc
- KO studies clearly prove the role of PAD4 in RA, SLE, DVT etc
- Targeting PAD4 does not lead to immune suppression nor risk of thrombocytopenia and may offer better therapeutic margin and safety
- Antibodies produced against citrullinated proteins (anti-CCP) are diagnostic, prognostic and stratification markers of RA
- Potential to target inflammation-driven diseases